Newsfeeds - Spark Newswire

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

October 19, 6:23 PM

Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.

AQB

2 minute read

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

By Charles Gross

September 11, 11:34 AM

Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte's plan to expand test availability in the U.S. and offer test globally as an in vitro diagnostic

VCYT

2 minute read

News

New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

By Michael Horton

September 7, 4:55 PM

Veracyte, Inc. (NASDAQ:VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary

VCYT

1 minute read

Needham Maintains Buy on Veracyte, Raises Price Target to $31

By Benzinga Newsdesk

August 3, 5:37 AM

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $26 to $31.

VCYT

1 minute read

Veracyte Q2 EPS $(0.13) Beats $(0.22) Estimate, Sales $72.86M Beat $68.08M Estimate

By Bill Haddad

August 2, 6:04 PM

Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.22) by 40.91 percent. This is unchanged from the same period last year. The company reported

VCYT

1 minute read

Earnings

Veracyte: Q2 Earnings Insights

By Benzinga Insights

August 2, 4:41 PM

Veracyte (NASDAQ:VCYT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by 40.91%, reporting an EPS of $-0.13 versus an estimate of $-0.22.

VCYT

17 minute read

Earnings Scheduled For August 2, 2022

By Benzinga Insights

August 2, 4:37 AM

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

ABNB

1 minute read

Earnings

Veracyte’s Earnings: A Preview

By Benzinga Insights

August 1, 1:10 PM

Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will report an earnings per share (EPS) of $-0.22.

VCYT

4 minute read

FDA
News

Veracyte Announces That New Data Show Immunoscore IC Assay May Predict Patients Likely To Benefit From Addition Of Immunotherapy To Standard First-line Therapy For Metastatic Colorectal Cancer

By Benzinga Newsdesk

May 31, 4:21 PM

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer Findings from Phase II

VCYT

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

May 11, 12:28 PM

On Wednesday, 807 companies reached new 52-week lows.

AADI